Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Early Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of PEEL-224 in Patients With Advanced Solid Tumors

Next Previous
Trial Profile

An Early Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of PEEL-224 in Patients With Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PEG [SN22]4 (Primary) ; Bevacizumab; Fluorouracil; Folinic acid
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors PEEL Therapeutics

Most Recent Events

  • 17 Jun 2025 Protocol amended to add third arm Part 2: PEEL-224 plus FOLF+B, patient number increased to 65.
  • 17 Jun 2025 Planned number of patients changed from 42 to 65.
  • 17 Jun 2025 Planned primary completion date changed from 1 Mar 2025 to 1 Dec 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top